In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model

Diagn Microbiol Infect Dis. 1992 Feb;15(2):173-6. doi: 10.1016/0732-8893(92)90045-u.

Abstract

The in vivo activity of the combination of daptomycin and fosfomycin against a beta-lactamase-producing, highly gentamicin-resistant strain of Enterococcus faecalis in a relapse model of rat endocarditis was studied. Minimum inhibitory concentrations (MICs) (micrograms per milliliter) for these agents against this strain were 4 (daptomycin) and 16 (fosfomycin). Time-kill studies demonstrated synergistic bactericidal activity when daptomycin (0.5 micrograms/ml) and fosfomycin (32 micrograms/ml) were combined. There was no significant difference between the number of valves sterilized by daptomycin alone [six (35%) of 17 valves sterilized] and daptomycin+fosfomycin [ten (59%) of 17 valves sterilized] p = 0.3. These results suggest that the in vitro bactericidal synergism demonstrable between these two agents against strains of enterococci will not necessarily translate into greater therapeutic efficacy in clinical infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Daptomycin
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination / pharmacology
  • Drug Therapy, Combination / therapeutic use
  • Endocarditis, Bacterial / drug therapy*
  • Enterococcus faecalis / drug effects*
  • Fosfomycin / pharmacology
  • Fosfomycin / therapeutic use*
  • Gram-Positive Bacterial Infections / drug therapy*
  • Male
  • Microbial Sensitivity Tests
  • Peptides / pharmacology
  • Peptides / therapeutic use
  • Rats
  • Rats, Inbred Strains

Substances

  • Peptides
  • Fosfomycin
  • Daptomycin